CTLA4 and neoplasm: The administration of tandem peptide nanocomplex (TPNC) carrying CpG DNA ligand of TLR9s (iTPNC) can suppress tumor growth in several animal models of various cancers, resulting in an abscopal effect on distant tumors, and improving responsiveness to anti-CTLA-4 treatment.